Logo Image
News
Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Watch
Expert ConversationsShows & PodcastNews & Analysis
Conferences
Conference CoverageConference Listing
Publications
More
CME/CE
Continuing Education
Resources
Case-Based Digest Rx Road MapEventsAdvanced Practice Corner
Partners

Subscribe

  • News
  • Watch
  • Conferences
  • Publications
  • CME/CE
  • Resources
  • Subscribe
  • Partners
  • Brain Cancer
  • Breast Cancer
    • Metastatic Breast Cancer
  • Gastrointestinal Cancer
    • Colorectal Cancer
    • Liver Cancer
    • Gastric Cancers
  • Genitourinary Cancer
    • Kidney Cancer
    • Bladder Cancer
    • Prostate Cancer
  • Gynecologic Cancers
    • Endometrial Cancer
    • Cervical Cancer
    • Ovarian Cancer
  • Head and Neck Cancers
  • Hematology
    • Leukemia
    • Graft-Vs-Host Disease
    • Myeloproliferative Neoplasms
    • Multiple Myeloma
    • Lymphoma
  • Lung Cancer
  • Pediatric Cancer
  • Sarcomas
  • Skin Cancer
    • Melanoma
Advertisement

Paula Anastasia, RN, MN, AOCN

Advertisement

Articles by Paula Anastasia, RN, MN, AOCN

Paula Anastasia on PARP Inhibitor Ineligibility Factors for Women With Ovarian Cancer

Paula Anastasia on PARP Inhibitor Ineligibility Factors for Women With Ovarian Cancer

ByPaula Anastasia, RN, MN, AOCN
August 8th 2022

Paula Anastasia, RN, MN, AOCN, highlights circumstances in which patients may not be eligible to receive benefit with a PARP inhibitor.

Advertisement

Latest Updated Articles

  • Paula Anastasia on PARP Inhibitor Ineligibility Factors for Women With Ovarian Cancer
    Paula Anastasia on PARP Inhibitor Ineligibility Factors for Women With Ovarian Cancer

    August 8th 2022



Advertisement
Advertisement

Trending on Oncology Nursing News

1

Patient Safety First: How a CNS Bridges Oncology Research and the Bedside

2

FDA Grants Accelerated Approval to Dostarlimab in dMMR Rectal Cancer

3

Anktiva Plus BCG: 84% of Responders Cystectomy-Free at 3 Years

4

Tucatinib Maintenance for HER2+ Breast Cancer: What Nurses, PAs Should Know

5

Making Innovation Meaningful: Enabling Personalized Care in Multiple Myeloma

  • About Us
  • Editorial Board
  • Contact Us
  • CancerNetwork.com
  • CureToday.com
  • OncLive.com
  • TargetedOnc.com
  • Advertise
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us